The new AMD drugs are aimed at providing patients with vision in the long term
Dr Jordi Monés, MD, PhD, the Director of the Institut de la Màcula, has addressed the latest developments in studies related to age-related macular degeneration (AMD) at the 19th Euretina Congress, which was held in Paris on 5-8 September
The Director of the Institut de la Màcula, Dr Jordi Monés, MD, PhD, participated at the 19th Euretina Congress in Paris to analyse the latest developments in the approach to age-related macular degeneration (AMD) with other internationally prestigious ophthalmological leaders. He also presented a progress report on the clinical trials with the new-generation drugs that treat AMD.
On 5 September, Dr Monés took part in a debate for Medscape, the medical information and continuing education platform, together with Dr Frank Holz, the researcher and Professor of Ophthalmology at the University of Bonn, and Professor Anat Loewenstein, the Director of the Department of Ophthalmology at Tel Aviv Medical Center.
Moderated by Dr Robin Hamilton, an ophthalmologist at Moorfields Eye Hospital, the debate examined the new knowledge we have to differentiate and quantify the different types of fluid in the neovascular form of AMD in order to take the appropriate decisions on retreatment; with a view to extending the interval between treatments now that new longer-acting and more effective drugs are appearing, such as brolucizumab. “This is a disease where we want to provide patients with vision in the long term”, Dr Monés says.
“One of the important things we have seen is that fluctuations of fluid must be prevented”, the Director of the Institut de la Màcula explains, “therefore we have to attempt to free lesions from liquid as fast as possible, without allowing any fluid rebounds and fluctuations. The less the fluid fluctuation in the retina, the better the vision in the long term”.
During the session, the international opinion leaders in Ophthalmology discussed how to prevent fluctuations in different types of fluids so that patients enjoy improved vision in the long term; and how to incorporate new drugs with a longer duration: “This will enable us to treat patients not only for 2-3 years but for many more years, which is what is needed in the end so that vision is not lost in the medium term”, Dr Monés says.
At the 19th Euretina Congress, Dr Monés gave two presentations of new-generation, longer-acting drugs for the treatment of exudative and atrophic AMD: Clinical evidence for the role of Ang-2 in retinal diseases and The role of complement C3 in geographic atrophy, organised by Roche.
The first talk focused on the Phase II clinical trial with faricimab, a new drug with dual molecular therapeutic action. That is to say, a new monoclonal antibody that combines the anti-angiogenic action of the drugs currently used in AMD treatment with anti-inflammatory action (anti-VEGF and anti-Ang 2). Faricimab is promising with regard to possible greater efficacy and duration for never-treated patients.
Meanwhile, the second presentation provided an explanation of the Phase III trial in which the aim is to slow the progression of atrophic AMD.